002900
vs
S
Shanghai Composite
002900
Over the past 12 months, Harbin Medisan Pharmaceutical Co Ltd has underperformed Shanghai Composite, delivering a return of -10% compared to the Shanghai Composite's +34% growth.
Stocks Performance
002900 vs Shanghai Composite
Performance Gap
002900 vs Shanghai Composite
Performance By Year
002900 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Harbin Medisan Pharmaceutical Co Ltd
Glance View
Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of chemical medicine preparations. The company is headquartered in Harbin, Heilongjiang and currently employs 1,519 full-time employees. The company went IPO on 2017-09-22. Its medicines cover the nervous system, cardio-cerebrovascular, systemic anti-infection, musculoskeletal, nutritional infusion, and body fluid balance infusion therapeutic fields. The firm's products include freeze-dried powder injections, small volume injections, large infusion products, solid preparations, medical devices and cosmetics. The firm mainly distributes its products within domestic market.
